Jim Cramer's 'Mad Money' CEO Chats: Regeneron and Alkermes

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) --Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Leonard Schleifer, president and CEO of Regeneron (REGN) and Richard Pops, chairman and CEO of drug maker Alkermes (AKLS), two of Cramer's favorite biotech plays.

These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 14, 2014.

Executive Decision: Leonard Schleifer

For his "Executive Decision" segment, Cramer spoke with Leonard Schleifer, president and CEO of Regeneron (REGN), which today announced continued successes with its drug Eyelea, as well as a promising pipeline that includes drugs for high cholesterol, arthritis, asthma and more.

Schleifer has a lot of positive things to say about Regeneron, noting that despite analysts' calls to the contrary, Eyelea has lots of room to grow thanks to favorable demographics, new geographies and hopefully new indications for the drug later in 2014. Regeneron is also making progress on its anti-cholesterol drug, which the company hopes to file for approval early next year.

Regeneron is also developing promising treatments for the epidemic of allergic diseases that are developing, as well as treatments for genetic ailments.

When asked about the possibility of re-incorporating in Ireland, where the company already has offices, Schleifer said that Regeneron loves New York, where it's headquartered, and has no plans to leave.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round